Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn

Clinical TrialsFDATherapuetics

Aug 27

Written By Corey Hubbard

GlassBury Cares Podcast

Episode #32

PfizerSickle CellResearchDr. Cece Calhoun

Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule